Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here are three stocks where Wall Street’s enthusiasm may be misplaced and some other investments worth exploring instead.
Somnigroup (SGI)
Consensus Price Target: $97.25 (35.9% implied return)
Established through the merger of Tempur-Pedic and Sealy in 2012, Somnigroup (NYSE: SGI) is a bedding manufacturer known for its innovative memory foam mattresses and sleep products
Why Do We Avoid SGI?
- Lackluster 14.5% annual revenue growth over the last five years indicates the company is losing ground to competitors
- Forecasted free cash flow margin suggests the company will fail to improve its cash conversion over the next year
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
Somnigroup’s stock price of $71.56 implies a valuation ratio of 21.9x forward P/E. To fully understand why you should be careful with SGI, check out our full research report (it’s free).
Planet Fitness (PLNT)
Consensus Price Target: $66.53 (24.4% implied return)
Founded by two brothers who purchased a struggling gym, Planet Fitness (NYSE: PLNT) is a gym franchise that caters to casual fitness users by providing a friendly and inclusive atmosphere.
Why Should You Sell PLNT?
- Weak same-store sales trends over the past two years suggest there may be few opportunities in its core markets to open new locations
- Capital intensity will likely increase as its free cash flow margin is anticipated to drop by 6.6 percentage points over the next year
- Returns on capital haven’t budged, indicating management couldn’t drive additional value creation
At $53.48 per share, Planet Fitness trades at 16.5x forward P/E. Dive into our free research report to see why there are better opportunities than PLNT.
Enovis (ENOV)
Consensus Price Target: $40.73 (50.7% implied return)
With a focus on helping patients regain or maintain their natural motion, Enovis (NYSE: ENOV) develops and manufactures medical devices for orthopedic care, from injury prevention and pain management to joint replacement and rehabilitation.
Why Are We Bearish on ENOV?
- Annual sales declines of 2.3% for the past five years show its products and services struggled to connect with the market during this cycle
- Negative returns on capital show management lost money while trying to expand the business, and its shrinking returns suggest its past profit sources are losing steam
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
Enovis is trading at $27.03 per share, or 7.1x forward P/E. Check out our free in-depth research report to learn more about why ENOV doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
